Bcl-2 and bcl-xL Antisense Oligonucleotides Induce Apoptosis in Melanoma Cells of Different Clinical Stages
- 1 March 2002
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 118 (3) , 505-512
- https://doi.org/10.1046/j.0022-202x.2001.01677.x
Abstract
No abstract availableKeywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31-40473.94, 31-55727.98)
This publication has 24 references indexed in Scilit:
- Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic OriginsJNCI Journal of the National Cancer Institute, 2001
- Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potentialDrug Resistance Updates, 2001
- Chemosensitisation of malignant melanoma by BCL2 antisense therapyThe Lancet, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- Higher Frequency of Selective Losses of HLA-A and -B Allospecificities in Metastasis Than in Primary Melanoma LesionsJournal of Investigative Dermatology, 1998
- Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell linesMelanoma Research, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic NeviThe American Journal of Dermatopathology, 1995
- Immunohistochemical expression of BCL‐2 in melanomas and intradermal neviJournal of Cutaneous Pathology, 1994
- Apoptosis in cancer therapy: Crossing the thresholdCell, 1994